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We herein report a case in which the recently characterized species Mycobacterium mo-
nacense was isolated from the sputum of an Iranian patient. This case represents the first 
isolation of M. monacense from Iran. The isolate was identified by conventional and mo-
lecular techniques. Our findings show that M. monacense infection is not restricted to de-
veloped countries.
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INTRODUCTION
Mycobacterium monacense is a rapidly growing Mycobacterium 
(RGM) that was first isolated from independent clinical speci-
mens in 2006 [1]. Subsequently, 3 additional studies from the 
United States, Germany, and India have reported the isolation of 
M. monacense from human clinical samples [2-4]. Here, we re-
port the first case of human isolate of M. monacense from a 
chronic respiratory infection in Iran identified by a combination 
of phenotypic and molecular tests.
CASE REPORT
A 57-yr-old female was admitted to a hospital in the suburb of 
Isfahan, Iran, for respiratory impairment with chronic productive 
cough and chest pain. She had no history of mycobacterial in-
fection. A purified protein derivative (PPD) skin test was positive 
to 5 TU (>12 mm). A chest X radiograph revealed clusters of 
small (>5 mm) nodules. Based on radiological findings, a posi-
tive tuberculin test, the presence of acid-fast bacilli (AFB) in a 
direct smear of sputum, and isolation of the same strain on 3 
repeated examinations, the patient was prescribed anti-tubercu-
losis drugs and was entered into the tuberculosis register. How-
ever, an examination of the cultured infecting organism revealed 
a yellow-pigmented, rapidly growing scotochromogenic Myco-
bacterium. Therefore, following the primary identification of the 
causative agent, the patient’s treatment was changed to combi-
nation therapy with amikacin and ciprofloxacin. After the initial 
45 days of the anti-tuberculosis therapy and the following 45 
days of antimicrobial therapy of non-tuberculous pulmonary in-
fection, the patient’s general condition improved. Her sputum 
smears and culture became negative and remained negative at 
each follow-up examination every 3 months. After discharge 
from hospital, the patient received a 12-month course of contin-Shojaei H, et al.
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ued treatment at a peripheral center affiliated with the national 
health care system. During the 24-month follow-up period, the 
patient did not relapse.
  A battery of conventional phenotypic and molecular tests was 
used to conclusively identify the M11 strain. The phenotypic 
tests were carried out using standard culture and biochemical 
methods, as previously described [5]. The susceptibility of the 
isolate “M11” to major anti-mycobacterial agents was performed 
using the microdilution method for rapidly growing mycobacte-
ria [6]. For molecular testing a panel of previously defined mo-
lecular markers for mycobacteria were used including, PCR 
amplification of a genus-specific region of the 65-kDa heat shock 
protein (hsp) gene [7], PCR restriction fragment length polymor-
phism analysis (PRA) of a 644-bp fragment of the hsp65 gene 
[8], amplification and direct sequence analysis of the near-full 
length 16S rDNA and 16S-23S rDNA internal transcribed spacer 
(ITS) genes, and amplification and direct sequence analysis of 
partial hsp65 and rpoB genes [9-13]. The GenBank accession 
numbers of the M11 strain genetic markers in the present study 
are GU142931, HM229791, HM229792, and HM229793.
  Acid-fast bacilli were observed by microscopic evaluation of 
the sputum sample; the organism was then cultured on Löwen-
stein-Jensen (LJ) medium. The same isolate was isolated from 3 
consecutive sputum samples. The M11 isolate was a rapidly 
growing (<7 days), scotochromogenic Mycobacterium capable 
of growth at 25°C, 37°C, and 45°C. Subcultures of the primary 
isolate had both smooth and rough colony types. Strain M11 was 
positive for semi-quantitative (100-mm foam) and heat-stable 
(68°C) catalases, nitrate reduction, Tween
® hydrolysis, growth on 
LJ medium with 5% NaCl, and tellurite reduction. Strain M11 
was negative for urease activity, growth on MacConkey agar with-
out crystal violet, arylsulfatase activity (14 days), niacin produc-
tion, and iron uptake. The M11 isolate was susceptible to amika-
cin (≤1 µg/mL), cefoxitin (2 µg/mL), ciprofloxacin (≤0.12 µg/
mL), clarithromycin (≤0.12 µg/mL), doxicyclin (≤1 µg/mL), eth-
ambutol (≤0.5 µg/mL), imipenem (1 µg/mL), rifampicin (≤0.06 
µg/mL), streptomycin (2 µg/mL), and sulfamethoxazol (1 µg/mL).
  Genus-specific PCR amplification yielded a characteristic 
228-bp fragment of the hsp65 gene, confirming that strain M11 
belonged to the genus Mycobacterium. The M11 isolate had a 
short helix 18 in the 16S rDNA gene, which is a typical molecu-
lar signature of rapidly growing mycobacteria.
  In the PRA method targeting the 644-bp fragment, the M11 
isolate’s restriction profile consisted of 456/180-bp, 270/161/117-
bp and 320/207-bp fragments from digestion with AvaII, HphI, 
and HpaII, respectively. This restriction profile is distinct from 
those of other previously characterized atypical mycobacteria 
(Fig. 1). 
  The near-full length (1,438-bp) 16S rDNA gene sequence of 
the M11 isolate shared 99.93% identity with that of M. mona-
cense DSM44395
T, 99.23% identity with that of M. doricum 
DSM44339
T, and 97.89% identity with that of M. vaccae ATCC 
15483
T. Accordingly, there were 1, 13, and 29 nucleotide differ-
ences, respectively. The first and second hypervariable signa-
ture sequences of the M11 isolate (positions 128-270 and 408-
503; Escherichia coli numbering) shared 100% identity with 
those of the M. monacense type strain (Table 1). 
  In a phylogeny generated using the 16S rDNA gene, the M11 
isolate was classified as an RGM species, and was closely re-
lated to M. monacense (Fig. 2). 
  The M11 isolate’s hsp65 gene sequence shared 99.09% iden-
tity with that of M. monacense. Its ITS gene sequence also shared 
97.83% identity with that of M. monacense clone F1-05352. The 
M11 isolate’s 745-bp fragment of the rpoB gene had a unique 
sequence compared to those of other atypical mycobacteria; 
however a comparison was not made between the M11 isolate 
and of the M. monacense type strain because its relevant data 
was not available in the molecular databases.
DISCUSSION
In countries with limited resources, such as Iran, the identifica-
tion of non-tuberculous mycobacteria (NTM) species by only 
Fig. 1. PCR restriction fragment length polymorphism patterns ob-
tained from digestion of the amplified hsp65 gene of the isolate 
“M11” with HphI (A), HpaII (B) and AvaII (C), respectively. MW:     
the 50 bp molecular weight marker. 
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routine conventional tests (e.g., direct microscopy and culture 
analysis) may result in erroneous or incomplete diagnosis. As a 
result, infections caused by these organisms may be underdiag-
nosed or misdiagnosed and, accordingly, mistreated [14, 15]. 
Fortunately, the use of molecular tests in conjunction with con-
ventional phenotypic tests has shown significant promise in ac-
curately identifying clinically relevant NTM [14-16].
  In 2006, M. monacense was first characterized as a new spe-
cies following its isolation from the bronchial lavage of an elderly 
patient and from a biopsy of an injury-acquired fistula in a healthy 
child [1]. Since then, 3 additional cases of M. monacense isola-
tion from clinical samples have been published. Taieb et al. [2] 
reported the isolation of M. monacense from a hand infection of 
an American diabetic patient. Hogardt et al. [3] reported a pul-
monary tuberculosis-like infection in a Chinese patient who had 
traveled to Europe, suggesting that it might have originated in 
China. In the most recent report, Therese et al. reported the first 
case of M. monacense isolation from the sputum of a female pa-
tient in India [4]. 
  In all but one of the reported cases, the clinical significance 
of isolation of M. monacense remains uncertain. Specifically, 
Hogardt et al. [3] presented the only case of a pulmonary dis-
ease associated with M. monacense which was isolated from a 
pulmonary tumor of a Chinese patient. The current report de-
scribed a pulmonary disease attributable to infection with M. 
monacense; this could support a clinically relevant role for this 
organism. In addition to its phenotypic features, the molecular 
tests used in the current study suggested that the Iranian isolate 
belonged to the M. monacense species. Specifically, it shared 
the highest identity with the 16S rDNA and hsp65 gene se-
quences of M. monacense, as opposed to those of other pub-
lished mycobacteria.
  The M11 isolate was considered the causative agent of dis-
ease in this case, because the acid-fast bacilli were microscopi-
Table 1. Alignment of selected stretches of 16S rDNA gene of Iranian strain of  M11 compared with those of closely related mycobacteria
Strain
Genbank 
accession number
16S rDNA positions according to E. coli numbering system
95 96 97 181 183 184 186 192 193 193 194 258 262 264 268 269 307 407 441 464 465 466 467
M. monacense DSM44395
T AF 107039 T A C A C G C G C G G A T C T C C G A G C A A
M. doricum DSM44339
T AF 264700 · G · · · · T A · · · · · · · · T · · · T G ·
M. flavescens ATCC14474
T X52932 · · · · T · · · · A · G G T C T · A G · · · ·
M 11 GU142931 · G · · Y · · · · · · · · · · · · · · · · · ·
“·”Indicates that the base pair was identical to that of type strain of M. monacense.
M. rhodesiae DSM 44223
T 100
36
32
48
39
26
34
73
99
99
91
100
0.005
94
100
6
35
34 M. aromaticivorans ATCC BAA-1378
T
M. rutilum ATCC BAA-1375
T
M. fortuitum ATCC 6841
T
M. porcinum CIP 105392
T
M. parafortuitum DSM 43528
T
M. duvalii ATCC 43910
T
M. smegmatis ATCC 19420
M. barrassiae CIP 108545
T
M. phlei ATCC 11758
T
M. novocastrense DSM 44203
T
M. doricum DSM 44339
T
M. monacense DSM 44395
T
M. monacense strain M11
M. vanbaalenii DSM 7251
T
M. vaccae ATCC 15483
T
Nocardia asteroides ATCC19247
T
M. moriokaense DSM 44221
T
M. flavescens strain ATCC 14474 
M. fortuitum subsp fortuitum ATCC 49404
T
Fig. 2. Alignment of selected stretches of 16S rDNA gene of the Iranian isolate  “M11” compared with those of closely related mycobacteria.Shojaei H, et al.
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cally observed in more than one diseased specimen and were 
subsequently recovered from a pure culture. Furthermore, no 
such organism had been isolated in our laboratory previously or 
during the same time. Our case also met the minimum evalua-
tion criteria for patients suspected of non-tuberculous mycobac-
terial lung disease set by the American Thoracic Society [17]. 
These criteria include pulmonary symptoms, a positive chest ra-
diograph, and 3 sputum specimens positive for AFB.
  This report follows a case in the United States, which con-
firms Hogardt’s suggestion that M. monacense infection is not 
restricted to Europe [12]. Consistent with previous reports on 
most non-tuberculous mycobacteria, our findings indicate that 
molecular markers are important for the identification of rare 
clinical isolates of atypical mycobacteria. Consequently, we rec-
ommend that developing countries centralize the laboratory di-
agnosis of rare NTM to a regional referral laboratory in order to 
avoid misidentification.
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